|1.||Müller, Thomas: 7 articles (06/2014 - 03/2006)|
|2.||Gordin, A: 7 articles (10/2004 - 05/2000)|
|3.||Leinonen, Mika: 5 articles (12/2015 - 05/2005)|
|4.||Poewe, Werner: 5 articles (12/2015 - 01/2004)|
|5.||Rascol, Olivier: 5 articles (07/2013 - 09/2004)|
|6.||Hauser, Robert A: 5 articles (07/2009 - 01/2004)|
|7.||Bremen, Dirk: 5 articles (05/2007 - 01/2004)|
|8.||Kaakkola, S: 5 articles (09/2006 - 06/2000)|
|9.||Brooks, D J: 5 articles (03/2005 - 04/2000)|
|10.||Kuoppamäki, Mikko: 4 articles (12/2015 - 06/2008)|
|1.||Parkinson Disease (Parkinson's Disease)
08/01/2003 - "Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study."
10/01/2004 - "Significant improvement with entacapone treatment was detected in several quality-of-life measures, including the Parkinson Disease Questionnaire 39, the 36-item Short-Form Health Survey, the Parkinson's Symptom Inventory, and investigator and subject Clinical Global Assessments. "
07/01/2001 - "The study shows that entacapone is a cost-effective treatment in patients with Parkinson's disease: entacapone yields higher effectiveness in terms of both effectiveness measures (time without severe fluctuations and QALYs), while costs remain quite similar to those for usual care. "
03/01/2007 - "Long-term effectiveness and quality of life improvement in entacapone-treated Parkinson's disease patients: the effects of an early therapeutic intervention."
08/01/2004 - "The efficacy of entacapone and its impact on patient quality of life (QOL) was investigated in an open-label study of 899 patients with idiopathic Parkinson's Disease (PD) experiencing wearing-off fluctuations. "
08/01/1999 - "In these and other phase III studies, entacapone was generally well tolerated, with most adverse effects being dyskinesias and gastrointestinal disorders. "
04/16/1999 - "In these and other phase III studies, entacapone was generally well tolerated, with few reported adverse events, mainly dyskinesias and gastrointestinal disorders. "
05/01/2015 - "In advanced PD patients with motor fluctuations, IPX066 reduced off time and increased on time without troublesome dyskinesia compared to CD-LD immediate release and CD-LD with entacapone. "
01/01/2010 - "CLE is an attractive alternative for patients with nondisabling "wearing-off" or dyskinesia taking CL with or without entacapone. "
06/01/2007 - "Even though entacapone is indicated for advanced PD patients with motor fluctuation, the fluctuators commonly have dyskinesia and mental symptoms, which can become more troublesome with entacapone. "
|3.||Schizophrenia (Dementia Praecox)
02/01/2014 - "To assess the efficacy of entacapone addition to antipsychotic treatment in patients with residual schizophrenia, we conducted a double-blind, randomised, placebo-controlled study for 12 wk of treatment with entacapone or placebo. "
02/01/2014 - "Therefore, this study does not support a therapeutic role for entacapone in residual schizophrenia. "
12/01/2011 - "Retrospective analysis, using the Bonferroni correction, of UPDRS motor subdomains further revealed that rasagiline, but not entacapone, significantly improved bradykinesia (P < 0.001) and showed trends for improvements in facial expression, speech, and axial impairment during OFF time. "
|5.||Dyspnea (Shortness of Breath)
|1.||Levodopa (L Dopa)
|4.||Catechol O-Methyltransferase (Methyltransferase, Catechol)
|7.||levodopa drug combination carbidopa (Nakom)
|10.||Complement System Proteins (Complement)
|1.||Activities of Daily Living (ADL)